Do analysts prefer PRME or TLSA?

Prime Medicine presently has a consensus price target of $7.53, indicating a potential upside of 141.77%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prime Medicine is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation and earnings, PRME or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Prime Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prime Medicine $4.63M 121.52 -$201.14M -$1.23 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media favor PRME or TLSA?

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Prime Medicine. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 1.63 beat Tiziana Life Sciences' score of 1.05 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend TLSA or CTMX?

CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 252.15%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91

Which has preferable valuation and earnings, TLSA or CTMX?

CytomX Therapeutics has higher revenue and earnings than Tiziana Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A CytomX Therapeutics $76.20M 7.67 -$17.37M -$0.41 N/A

Does the media refer more to TLSA or CTMX?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for CytomX Therapeutics and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat CytomX Therapeutics' score of 0.60 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NGNE or TLSA?

Neurogene presently has a consensus price target of $84.83, suggesting a potential upside of 129.47%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable valuation and earnings, NGNE or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than Neurogene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neurogene $930K 628.08 -$90.35M -$4.55 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is NGNE or TLSA more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Tiziana Life Sciences N/A N/A N/A

Does the media favor NGNE or TLSA?

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.34 beat Tiziana Life Sciences' score of 1.05 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TLSA or AVTE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, TLSA or AVTE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is TLSA or AVTE more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A Aerovate Therapeutics N/A -90.19% -77.47%

Which has stronger valuation and earnings, FDMT or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than 4D Molecular Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4D Molecular Therapeutics $85.21M 7.15 -$140.11M -$2.57 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Does the media favor FDMT or TLSA?

In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat 4D Molecular Therapeutics' score of 0.31 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tiziana Life Sciences (TLSA) Competitors

$1.00 -0.02 (-1.48%)

As of 11:08 AM Eastern

Compare

TLSA vs. PRME, CTMX, NGNE, AVTE, and FDMT

Should you buy Tiziana Life Sciences stock or one of its competitors? MarketBeat compares Tiziana Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tiziana Life Sciences include Prime Medicine (PRME), CytomX Therapeutics (CTMX), Neurogene (NGNE), Aerovate Therapeutics (AVTE), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry.

How does Tiziana Life Sciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Tiziana Life Sciences has lower revenue, but higher earnings than Prime Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	121.52	-$201.14M	-$1.23	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Prime Medicine. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 1.63 beat Tiziana Life Sciences' score of 1.05 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tiziana Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine has a beta of 2.26, meaning that its stock price is 126% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Prime Medicine presently has a consensus price target of $7.53, indicating a potential upside of 141.77%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prime Medicine is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

70.4% of Prime Medicine shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Tiziana Life Sciences' return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Tiziana Life Sciences	N/A	N/A	N/A

Summary

Prime Medicine beats Tiziana Life Sciences on 8 of the 14 factors compared between the two stocks.

How does Tiziana Life Sciences compare to CytomX Therapeutics?

Tiziana Life Sciences (NASDAQ:TLSA) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

67.8% of CytomX Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tiziana Life Sciences has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Tiziana Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
CytomX Therapeutics	$76.20M	7.67	-$17.37M	-$0.41	N/A

Tiziana Life Sciences has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Tiziana Life Sciences' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, CytomX Therapeutics had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 3 mentions for CytomX Therapeutics and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat CytomX Therapeutics' score of 0.60 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 252.15%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Summary

CytomX Therapeutics beats Tiziana Life Sciences on 9 of the 14 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Neurogene has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Tiziana Life Sciences has lower revenue, but higher earnings than Neurogene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	628.08	-$90.35M	-$4.55	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Neurogene presently has a consensus price target of $84.83, suggesting a potential upside of 129.47%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Tiziana Life Sciences' return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Neurogene. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 1 mentions for Neurogene. Neurogene's average media sentiment score of 1.34 beat Tiziana Life Sciences' score of 1.05 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tiziana Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

52.4% of Neurogene shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Neurogene beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.

How does Tiziana Life Sciences compare to Aerovate Therapeutics?

Tiziana Life Sciences (NASDAQ:TLSA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Tiziana Life Sciences has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Tiziana Life Sciences' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 0 mentions for Aerovate Therapeutics. Tiziana Life Sciences' average media sentiment score of 1.05 beat Aerovate Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Positive
Aerovate Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Tiziana Life Sciences beats Aerovate Therapeutics on 6 of the 7 factors compared between the two stocks.

How does Tiziana Life Sciences compare to 4D Molecular Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Tiziana Life Sciences has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -182.34%. Tiziana Life Sciences' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-182.34%	-36.83%	-32.55%
Tiziana Life Sciences	N/A	N/A	N/A

In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 2 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.05 beat 4D Molecular Therapeutics' score of 0.31 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tiziana Life Sciences has lower revenue, but higher earnings than 4D Molecular Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	7.15	-$140.11M	-$2.57	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

4D Molecular Therapeutics presently has a consensus target price of $29.88, indicating a potential upside of 156.22%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

4D Molecular Therapeutics has a beta of 2.7, suggesting that its stock price is 170% more volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Summary

4D Molecular Therapeutics beats Tiziana Life Sciences on 7 of the 13 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSA vs. The Competition

Export

Metric	Tiziana Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$127.26M	$3.64B	$6.80B	$12.40B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	N/A	20.61	27.08	24.12
Price / Sales	N/A	304.69	516.47	92.58
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	N/A	8.04	10.63	6.23
Net Income	-$18.43M	$23.81M	$3.60B	$331.53M
7 Day Performance	-19.35%	-1.31%	-1.08%	-1.30%
1 Month Performance	-13.79%	2.48%	1.28%	-1.40%
1 Year Performance	-38.27%	44.40%	24.71%	18.15%

Tiziana Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSA Tiziana Life Sciences	0.7449 of 5 stars	$1.00 -1.5%	N/A	-34.5%	$127.26M	N/A	N/A	8	Positive News Gap Up
PRME Prime Medicine	3.3234 of 5 stars	$3.48 -1.3%	$7.53 +116.7%	N/A	$627.65M	$4.63M	N/A	N/A	Positive News
CTMX CytomX Therapeutics	2.2601 of 5 stars	$3.66 -1.1%	$12.10 +230.6%	+47.9%	$623.75M	$76.20M	N/A	170	Positive News
NGNE Neurogene	3.4024 of 5 stars	$39.08 +2.0%	$84.83 +117.1%	+67.1%	$617.42M	$930K	N/A	90	Positive News
AVTE Aerovate Therapeutics	N/A	$21.30 +1.7%	N/A	+120.3%	$617.38M	N/A	N/A	20	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. PRME, CTMX, NGNE, AVTE, and FDMT

How does Tiziana Life Sciences compare to Prime Medicine?

Summary

How does Tiziana Life Sciences compare to CytomX Therapeutics?

Summary

How does Tiziana Life Sciences compare to Neurogene?

Summary

How does Tiziana Life Sciences compare to Aerovate Therapeutics?

Summary

How does Tiziana Life Sciences compare to 4D Molecular Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tiziana Life Sciences (TLSA) Competitors

TLSA vs. PRME, CTMX, NGNE, AVTE, and FDMT

How does Tiziana Life Sciences compare to Prime Medicine?

Which has stronger valuation and earnings, PRME or TLSA?

Does the media favor PRME or TLSA?

Which has more volatility & risk, PRME or TLSA?

Do analysts prefer PRME or TLSA?

Do insiders and institutionals believe in PRME or TLSA?

Is PRME or TLSA more profitable?

Summary

How does Tiziana Life Sciences compare to CytomX Therapeutics?

Do institutionals and insiders hold more shares of TLSA or CTMX?

Which has more volatility and risk, TLSA or CTMX?

Which has preferable valuation and earnings, TLSA or CTMX?

Is TLSA or CTMX more profitable?

Does the media refer more to TLSA or CTMX?

Do analysts recommend TLSA or CTMX?

Summary

How does Tiziana Life Sciences compare to Neurogene?

Which has more risk & volatility, NGNE or TLSA?

Which has preferable valuation and earnings, NGNE or TLSA?

Do analysts recommend NGNE or TLSA?

Is NGNE or TLSA more profitable?

Does the media favor NGNE or TLSA?

Do institutionals & insiders hold more shares of NGNE or TLSA?

Summary

How does Tiziana Life Sciences compare to Aerovate Therapeutics?

Which has more volatility and risk, TLSA or AVTE?

Which has higher valuation and earnings, TLSA or AVTE?

Is TLSA or AVTE more profitable?

Does the media prefer TLSA or AVTE?

Do analysts prefer TLSA or AVTE?

Summary

How does Tiziana Life Sciences compare to 4D Molecular Therapeutics?

Is FDMT or TLSA more profitable?

Does the media favor FDMT or TLSA?

Which has stronger valuation and earnings, FDMT or TLSA?

Do analysts rate FDMT or TLSA?

Do institutionals & insiders have more ownership in FDMT or TLSA?

Which has more volatility & risk, FDMT or TLSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSA vs. The Competition

Tiziana Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools